AnaptysBio’s (ANAB) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of AnaptysBio (NASDAQ:ANAB) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $19.00 price objective on the biotechnology company’s stock.

A number of other brokerages also recently commented on ANAB. Guggenheim reduced their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. JPMorgan Chase & Co. decreased their price objective on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Wells Fargo & Company lowered their price objective on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research report on Thursday, December 12th. Truist Financial reduced their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Finally, BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.08.

AnaptysBio Stock Performance

Shares of AnaptysBio stock opened at $16.08 on Tuesday. The business’s 50 day moving average price is $16.87 and its 200 day moving average price is $26.69. The company has a market cap of $489.30 million and a price-to-earnings ratio of -2.64. AnaptysBio has a one year low of $12.51 and a one year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. On average, analysts predict that AnaptysBio will post -6.08 EPS for the current fiscal year.

Insiders Place Their Bets

In other AnaptysBio news, Director Ecor1 Capital, Llc purchased 6,646 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was acquired at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the purchase, the director now directly owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ANAB. Values First Advisors Inc. acquired a new stake in AnaptysBio in the 3rd quarter valued at about $49,000. nVerses Capital LLC increased its stake in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after buying an additional 1,400 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in AnaptysBio by 81.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 2,600 shares in the last quarter. Point72 DIFC Ltd lifted its stake in AnaptysBio by 680.5% in the third quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 5,342 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in AnaptysBio during the 3rd quarter worth approximately $229,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.